357 related articles for article (PubMed ID: 23563402)
1. Biosimilars battle rages on, Amgen fights both sides.
Senior M
Nat Biotechnol; 2013 Apr; 31(4):269-70. PubMed ID: 23563402
[No Abstract] [Full Text] [Related]
2. The comparability conundrum: biosimilars in the United States, Europe and Canada.
Courage N; Parsons A
Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
[TBL] [Abstract][Full Text] [Related]
3. Biotech innovators jump on biosimilars bandwagon.
Moran N
Nat Biotechnol; 2012 Apr; 30(4):297-9. PubMed ID: 22491261
[No Abstract] [Full Text] [Related]
4. Considerations in the early development of biosimilar products.
Li EC; Abbas R; Jacobs IA; Yin D
Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
[TBL] [Abstract][Full Text] [Related]
5. Regulatory considerations in biosimilars: Asia pacific regions.
Rathore AS; Bhargava A
Prep Biochem Biotechnol; 2021; 51(1):1-8. PubMed ID: 32921222
[TBL] [Abstract][Full Text] [Related]
6. First biosimilar drug approved for sale in the United States.
Hede K
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142444
[No Abstract] [Full Text] [Related]
7. Biosimilars in the Caribbean--key considerations.
Cox SD
West Indian Med J; 2012 Dec; 61(9):849-52. PubMed ID: 24020222
[No Abstract] [Full Text] [Related]
8. Effective pharmaceutical regulation needs alignment with doctors.
Ebbers HC; Pieters T; Leufkens HG; Schellekens H
Drug Discov Today; 2012 Feb; 17(3-4):100-3. PubMed ID: 22001600
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars Ready, At Last, To Make Their Entrance: Stars Are Born or Do They Fizzle?
Reinke T
Manag Care; 2017 Mar; 26(3):20-23. PubMed ID: 28510515
[TBL] [Abstract][Full Text] [Related]
10. Drug Development. Are trade secrets delaying biosimilars?
Price WN; Rai AK
Science; 2015 Apr; 348(6231):188-9. PubMed ID: 25859034
[No Abstract] [Full Text] [Related]
11. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
12. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
13. First US biosimilar edges towards market.
Senior M
Nat Biotechnol; 2015 Mar; 33(3):222-3. PubMed ID: 25748898
[No Abstract] [Full Text] [Related]
14. 10 years of biosimilars: lessons and trends.
Royzman I; Shah K
Nat Rev Drug Discov; 2020 Jun; 19(6):375. PubMed ID: 32358591
[No Abstract] [Full Text] [Related]
15. FDA sets hierarchy for biosimilars evidence.
Ratner M
Nat Biotechnol; 2014 Jul; 32(7):609. PubMed ID: 25004221
[No Abstract] [Full Text] [Related]
16. The brave new world of biosimilars ('similar biologics') in India.
Jois R
Postgrad Med J; 2017 Oct; 93(1104):577-579. PubMed ID: 28546231
[No Abstract] [Full Text] [Related]
17. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
18. Bracing for the biosimilar wave.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):152-154. PubMed ID: 28248938
[No Abstract] [Full Text] [Related]
19. Core Concepts: Biosimilars.
Ornes S
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15261-2. PubMed ID: 26672105
[No Abstract] [Full Text] [Related]
20. The Biosimilar Pipeline Seams Seem To Be Bursting.
Reinke T
Manag Care; 2017 Mar; 26(3):24-25. PubMed ID: 28510516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]